CA3228601A1 - Novel plk1 degradation inducing compound - Google Patents
Novel plk1 degradation inducing compound Download PDFInfo
- Publication number
- CA3228601A1 CA3228601A1 CA3228601A CA3228601A CA3228601A1 CA 3228601 A1 CA3228601 A1 CA 3228601A1 CA 3228601 A CA3228601 A CA 3228601A CA 3228601 A CA3228601 A CA 3228601A CA 3228601 A1 CA3228601 A1 CA 3228601A1
- Authority
- CA
- Canada
- Prior art keywords
- mmol
- cancer
- amino
- mixture
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210105358 | 2021-08-10 | ||
| KR10-2021-0105358 | 2021-08-10 | ||
| KR10-2021-0106488 | 2021-08-12 | ||
| KR20210106488 | 2021-08-12 | ||
| KR10-2021-0117389 | 2021-09-03 | ||
| KR20210117389 | 2021-09-03 | ||
| KR10-2021-0126757 | 2021-09-24 | ||
| KR20210126757 | 2021-09-24 | ||
| KR20220008456 | 2022-01-20 | ||
| KR10-2022-0008456 | 2022-01-20 | ||
| KR20220020996 | 2022-02-17 | ||
| KR10-2022-0020996 | 2022-02-17 | ||
| KR20220054880 | 2022-05-03 | ||
| KR10-2022-0054880 | 2022-05-03 | ||
| KR20220075838 | 2022-06-21 | ||
| KR10-2022-0075838 | 2022-06-21 | ||
| PCT/KR2022/011961 WO2023018236A1 (en) | 2021-08-10 | 2022-08-10 | Novel plk1 degradation inducing compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3228601A1 true CA3228601A1 (en) | 2023-02-16 |
Family
ID=85200656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3228601A Pending CA3228601A1 (en) | 2021-08-10 | 2022-08-10 | Novel plk1 degradation inducing compound |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US11939334B2 (enExample) |
| EP (4) | EP4157850A4 (enExample) |
| JP (4) | JP7555155B2 (enExample) |
| KR (5) | KR102604802B1 (enExample) |
| CN (2) | CN116261458B (enExample) |
| AU (1) | AU2022327025A1 (enExample) |
| CA (1) | CA3228601A1 (enExample) |
| CL (1) | CL2024000373A1 (enExample) |
| CO (1) | CO2024001256A2 (enExample) |
| CR (1) | CR20240120A (enExample) |
| EC (1) | ECSP24010109A (enExample) |
| IL (1) | IL310678A (enExample) |
| MX (1) | MX2024001774A (enExample) |
| PE (1) | PE20240894A1 (enExample) |
| WO (5) | WO2023017446A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230158158A1 (en) * | 2020-03-27 | 2023-05-25 | Uppthera | Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1 |
| JP7555155B2 (ja) * | 2021-08-10 | 2024-09-24 | オップテラ インコーポレイテッド | 新規ｐｌｋ１分解誘導化合物 |
| AU2022326463A1 (en) | 2021-08-10 | 2024-02-22 | Novartis Pharma Ag | Compounds and compositions for treating conditions associated with sting activity |
| CN120603831A (zh) * | 2022-11-29 | 2025-09-05 | 厄普特拉株式会社 | 具有增加的刚性的plk1降解诱导化合物 |
| EP4658658A1 (en) * | 2023-02-02 | 2025-12-10 | Uppthera, Inc. | Novel plk1 degradation inducing compound |
| CN118946561A (zh) * | 2023-03-10 | 2024-11-12 | 标新生物医药科技(上海)有限公司 | 新颖的e3泛素连接酶配体、蛋白降解剂及其应用 |
| TW202502750A (zh) | 2023-06-08 | 2025-01-16 | 美商新銳思生物製藥股份有限公司 | Smarca2之雙官能選擇性降解劑及其治療用途 |
| EP4759807A1 (en) | 2023-08-11 | 2026-06-17 | Shenzhen Zhongge Biological Technology Co., Ltd. | Proteolysis targeting chimera compound for degrading irak4 and use thereof |
| CN117126133B (zh) * | 2023-08-14 | 2026-06-30 | 中国海洋大学 | 一种化合物及其用途 |
| EP4780815A1 (en) | 2023-09-20 | 2026-07-29 | Aurigene Oncology Limited | Heterocyclic compounds as cbp selective degraders |
| US20250197411A1 (en) | 2023-12-14 | 2025-06-19 | Astrazeneca Ab | Irak4 protacs |
| WO2025239662A1 (ko) * | 2024-05-13 | 2025-11-20 | (주) 업테라 | 분해 약물-항체 접합체용 plk1 분해 유도 화합물 |
| CN118724841B (zh) * | 2024-06-14 | 2026-06-19 | 南通华祥医药科技有限公司 | 一种n-氨基哌啶二盐酸盐的制备方法 |
| WO2026013576A1 (en) * | 2024-07-10 | 2026-01-15 | Monte Rosa Therapeutics Ag | Dihydrouracil derivatives useful for the targeted degradation of vav1 |
| WO2026013577A1 (en) * | 2024-07-10 | 2026-01-15 | Monte Rosa Therapeutics Ag | Piperidine-2, 6-dione derivatives useful for the targeted degradation of vav1 |
| WO2026026773A1 (zh) * | 2024-07-29 | 2026-02-05 | 杭州胶联生物医药科技有限公司 | 作为vav1蛋白靶点降解剂的新型取代杂环类化合物 |
| WO2026041138A1 (zh) * | 2024-08-22 | 2026-02-26 | 武汉人福创新药物研发中心有限公司 | 作为vav1降解剂的苯并杂环类化合物及其用途 |
| WO2026114368A1 (zh) * | 2024-11-28 | 2026-06-04 | 西藏海思科制药有限公司 | 一种vav1靶向降解剂及其用途 |
| WO2026114367A1 (zh) * | 2024-11-28 | 2026-06-04 | 西藏海思科制药有限公司 | Vav1靶向降解剂及其用途 |
| WO2026114343A1 (zh) * | 2024-11-29 | 2026-06-04 | 上海美悦生物科技发展有限公司 | 杂环化合物、及其药物组合物和用途 |
| WO2026158584A1 (zh) * | 2025-01-25 | 2026-07-30 | 杭州和正医药有限公司 | 多杂环类vav1降解分子衍生物及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2010542B1 (en) * | 2006-04-12 | 2012-01-25 | Vertex Pharmaceuticals Incorporated | 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridines as plk1 protein kinase inhibitors for the treatment of proliferative disorders |
| TW200808325A (en) | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
| CN101636399B (zh) | 2007-03-22 | 2012-04-18 | 武田药品工业株式会社 | 可用作plk1抑制剂的取代的嘧啶并二氮杂* |
| BRPI0817315A2 (pt) * | 2007-09-25 | 2015-03-17 | Takeda Pharmaceutical | Inibidores de quinase do tipo polo |
| WO2009153197A1 (en) * | 2008-06-18 | 2009-12-23 | F. Hoffmann-La Roche Ag | Halo-substituted pyrimidodiazepines as plkl inhibitors |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| BR112018008918A8 (pt) | 2015-11-02 | 2019-02-26 | Univ Yale | compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos |
| CN106543185B (zh) * | 2016-11-10 | 2017-12-15 | 吉林大学 | 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用 |
| IL319363A (en) * | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| CN106977584B (zh) * | 2017-04-19 | 2019-12-06 | 吉林大学 | 靶向泛素化降解plk1和brd4蛋白的化合物及其应用 |
| US20200038513A1 (en) * | 2018-07-26 | 2020-02-06 | Arvinas Operations, Inc. | Modulators of fak proteolysis and associated methods of use |
| CN111018857B (zh) * | 2018-10-09 | 2023-06-02 | 嘉兴优博生物技术有限公司 | 靶向蛋白酶降解平台(ted) |
| CN109879877B (zh) * | 2019-03-04 | 2021-08-10 | 吉林大学 | 一种可降解plk1和brd4蛋白的化合物及其应用 |
| EP4031247A1 (en) | 2019-09-16 | 2022-07-27 | Novartis AG | Bifunctional degraders and their methods of use |
| AU2020356484A1 (en) | 2019-09-27 | 2022-03-17 | Dana-Farber Cancer Institute, Inc. | ERK5 degraders as therapeutics in cancer and inflammatory diseases |
| US20230158158A1 (en) * | 2020-03-27 | 2023-05-25 | Uppthera | Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1 |
| JP7555155B2 (ja) * | 2021-08-10 | 2024-09-24 | オップテラ インコーポレイテッド | 新規ｐｌｋ１分解誘導化合物 |
-
2022
- 2022-08-10 JP JP2023514149A patent/JP7555155B2/ja active Active
- 2022-08-10 IL IL310678A patent/IL310678A/en unknown
- 2022-08-10 KR KR1020227036596A patent/KR102604802B1/ko active Active
- 2022-08-10 EP EP22808931.4A patent/EP4157850A4/en active Pending
- 2022-08-10 US US18/019,034 patent/US11939334B2/en active Active
- 2022-08-10 EP EP22855629.6A patent/EP4384520A4/en active Pending
- 2022-08-10 WO PCT/IB2022/057475 patent/WO2023017446A1/en not_active Ceased
- 2022-08-10 WO PCT/KR2022/011963 patent/WO2023018238A1/en not_active Ceased
- 2022-08-10 EP EP22808930.6A patent/EP4157849A4/en active Pending
- 2022-08-10 US US18/580,553 patent/US20250114460A1/en active Pending
- 2022-08-10 US US18/019,047 patent/US11912710B2/en active Active
- 2022-08-10 CN CN202280006544.1A patent/CN116261458B/zh active Active
- 2022-08-10 WO PCT/KR2022/011961 patent/WO2023018236A1/en not_active Ceased
- 2022-08-10 WO PCT/KR2022/011962 patent/WO2023018237A1/en not_active Ceased
- 2022-08-10 EP EP22856233.6A patent/EP4384521A4/en active Pending
- 2022-08-10 JP JP2024507884A patent/JP2024530195A/ja active Pending
- 2022-08-10 KR KR1020227042318A patent/KR102604803B1/ko active Active
- 2022-08-10 KR KR1020227036557A patent/KR102604801B1/ko active Active
- 2022-08-10 CA CA3228601A patent/CA3228601A1/en active Pending
- 2022-08-10 AU AU2022327025A patent/AU2022327025A1/en active Pending
- 2022-08-10 CR CR20240120A patent/CR20240120A/es unknown
- 2022-08-10 WO PCT/IB2022/057471 patent/WO2023017442A1/en not_active Ceased
- 2022-08-10 KR KR1020227046443A patent/KR102662205B1/ko active Active
- 2022-08-10 US US18/580,506 patent/US20250101025A1/en active Pending
- 2022-08-10 MX MX2024001774A patent/MX2024001774A/es unknown
- 2022-08-10 JP JP2024507883A patent/JP2024530495A/ja active Pending
- 2022-08-10 JP JP2023514160A patent/JP7555156B2/ja active Active
- 2022-08-10 KR KR1020247013823A patent/KR20240060721A/ko active Pending
- 2022-08-10 PE PE2024000208A patent/PE20240894A1/es unknown
- 2022-08-10 CN CN202280006505.1A patent/CN116322700B/zh active Active
-
2024
- 2024-02-06 CO CONC2024/0001256A patent/CO2024001256A2/es unknown
- 2024-02-06 CL CL2024000373A patent/CL2024000373A1/es unknown
- 2024-02-07 EC ECSENADI202410109A patent/ECSP24010109A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7555155B2 (ja) | 新規ｐｌｋ１分解誘導化合物 | |
| AU2021204556B2 (en) | Compounds and methods for the targeted degradation of androgen receptor | |
| EP4626555A1 (en) | Glutarimide-containing pan-kras-mutant degrader compounds and uses thereof | |
| CA3214806A1 (en) | Modulators of bcl6 proteolysis and associated methods of use | |
| US10676434B2 (en) | Carbazole derivatives | |
| WO2022266258A1 (en) | Compounds and methods for the targeted degradation of irak-4 | |
| CN110234646A (zh) | 靶向PROTAC的Tau蛋白及相关使用方法 | |
| CA2965517A1 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| EA035592B1 (ru) | Ингибиторы деацетилаз гистонов и композиции и способы их применения | |
| TW201602100A (zh) | 選擇性經取代之喹啉化合物 | |
| EA036965B1 (ru) | Ингибиторы деацетилаз гистонов и композиции и способы их применения | |
| CA3165669A1 (en) | Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds | |
| JP2024502106A (ja) | ｃ－ＭＹＣ ｍＲＮＡ翻訳調節因子及び癌治療におけるそれの使用 | |
| CA3203922A1 (en) | Enzyme inhibitors | |
| US12351577B2 (en) | Inhibiting cyclic AMP-responsive element-binding protein (CREB) | |
| CA3060990A1 (en) | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | |
| CA2963054A1 (en) | Piperidine substituted tricyclic pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (rsv) | |
| KR20250105638A (ko) | 경직성이 증가된 plk1 분해 유도 화합물 | |
| CA2542047A1 (en) | Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors | |
| JP2025530757A (ja) | 新規ｐｌｋ１分解誘導化合物 | |
| WO2024108009A1 (en) | Dyrk/clk protacs and uses thereof | |
| OA21863A (en) | Indazole based compounds and associated methods of use. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241231 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250805 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250805 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260715 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260715 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260717 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260717 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260806 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260806 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260806 |